Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hospital readmissions following infections in dementia: a nationwide and registry-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. European guideline and expert statements on the management of narcolepsy in adults and children

    Research output: Contribution to journalReviewResearchpeer-review

  4. Muscle involvement assessed by quantitative magnetic resonance imaging in patients with anoctamin 5 deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Gastrointestinal bleeding and the risk of colorectal cancer in anticoagulated patients with atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fascicular heart blocks and risk of adverse cardiovascular outcomes: results from a large primary care population

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND PURPOSE: Real-world evidence regarding the effectiveness and safety of ocrelizumab for the treatment of multiple sclerosis (MS) is limited. The aim was to evaluate the effectiveness and safety of ocrelizumab treatment for MS in a real-world setting.

METHODS: A nationwide population-based cohort study was conducted where clinical and magnetic resonance imaging data of MS patients enrolled prospectively in the Danish Multiple Sclerosis Registry who initiated ocrelizumab treatment between January 2018 and November 2020 were analyzed.

RESULTS: A total of 1104 patients (85.7% relapsing-remitting MS [RRMS], 8.8% secondary progressive MS [SPMS], 5.5% primary progressive MS [PPMS]) were included, with a median follow-up period of 1.3 years. At baseline, the mean age was 41.4 years in the RRMS group, 44.5 years in the PPMS group and 50.3 years in the SPMS group. Median Expanded Disability Status Scale score was 2.5, 3.5 and 5.5, respectively. Most RRMS and SPMS patients had received previous disease-modifying therapies (87.5% and 91.8%, respectively), whereas PPMS patients were mostly treatment naïve (78.7%). After ocrelizumab initiation, 9.3% of the patients experienced a relapse and 8.7% a 24 weeks confirmed disability worsening. Conversely, 16.7% showed a 24 weeks confirmed disability improvement. After ~1 year of treatment, most patients (94.5%) were free of magnetic resonance imaging activity. Ocrelizumab was generally well tolerated, as side effects were only reported for 10% of patients, mostly consisting of infusion-related reactions and infections.

CONCLUSIONS: It is shown that most MS patients treated with ocrelizumab are clinically stabilized and with an adverse event profile consistent with the experience from the pivotal clinical trials.

Original languageEnglish
JournalEuropean Journal of Neurology
Volume29
Issue number2
Pages (from-to)496-504
Number of pages9
ISSN1351-5101
DOIs
Publication statusPublished - Feb 2022

Bibliographical note

© 2021 European Academy of Neurology.

    Research areas

  • anti-CD20 monoclonal antibody, multiple sclerosis, ocrelizumab, real-world studies, registry

ID: 68605938